Cimdelirsen (sodium)
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
Product Specifications
CAS Number
2131025-83-5
Product Name Alternative
ISIS 766720 (sodium) ; IONIS-GHR-LRx (sodium)
UNSPSC
12352208
Target
GHR; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/cimdelirsen-sodium.html
Solubility
10 mM in H2O
Smiles
[Cimdelirsen(sodium)]
Molecular Formula
C296H415N83Na20O152P20S15
Molecular Weight
8688.55 (free acid)
References & Citations
[1]Bhanot S, Fleseriu M, Geary R, et al. OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients. J Endocr Soc. 2022;6 (Suppl 1) :A526.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-C987923-250MG 250 mg
(R)-2-Cyclohexyl-2-hydroxyphenylacetic Acid
Sign In for Pricing
View Details 
